<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Diamicron MR</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@400;700&display=swap" rel="stylesheet">
    <script src="https://cdn.tailwindcss.com"></script>

    <style>
        body {
            font-family: "Poppins", sans-serif;
        }
    </style>
</head>

<body>
    <!-- Header -->
    <header class="mb-2">

        <!-- ส่วนรูป -->
        <div class="relative w-full">

            <img src="./images/background-header.png" class="w-full h-auto" alt="background" />

            <!-- Logo -->
            <div class="absolute top-0 left-0 w-full flex justify-between">
                <div class="w-[150px] sm:w-[250px] md:w-[350px] lg:w-[420px] xl:w-[500px] p-4 sm:p-6 md:p-8 lg:p-10">
                    <img src="./images/logo.png" alt="logo">
                </div>
                <div class="w-[80px] sm:w-[150px] md:w-[200px] lg:w-[250px] xl:w-[300px] p-2">
                    <img src="./images/logo2.png" alt="logo2">
                </div>
            </div>

            <!-- Header text -->
            <div class="absolute top-[35%] sm:top-[50%] md:top-[40%] left-[5%] text-white">
                <h1 class="text-3xl sm:text-5xl md:text-7xl lg:text-8xl xl:text-9xl font-bold">
                    LATEST DATA
                </h1>
                <h3 class="text-xs sm:text-lg sm:text-2xl md:text-4xl lg:text-4xl xl:text-5xl mt-1 lg:mt-3">
                    On Highly Cost-Effective of Diamicron MR
                </h3>
            </div>

        </div>

        <!-- Header content -->
        <div class="relative z-10 -mt-16 sm:-mt-32 md:-mt-40 lg:-mt-52 xl:-mt-72 
                text-gray-500 text-sm md:text-2xl xl:text-2xl p-6 sm:p-8 md:p-10 lg:p-14 xl:p-20">
            <h3 class="mb-2 md:mb-4">Dear Doctor,</h3>
            <p>
                I am thrilled to inform you that, according to a new publication (2025), initiating Gliclazide modified
                release (MR) in patients who do not achieve adequate glycemic control with Metformin therapy can reduce
                cardiovascular events/deaths and their costs. Moreover, the same benefits can be observed when switching
                the add-on treatment from Sitagliptin to Gliclazide MR in combination with Metformin.
            </p>
        </div>

    </header>


    <!-- Section -->
    <section class="flex flex-col">

        <!-- Section one -->
        <div class="flex flex-col">
            <div
                class="text-white text-sm md:text-2xl p-6 sm:px-8 md:px-10 lg:px-14 xl:px-20 bg-orange-500 rounded-r-full w-[90%] xl:w-[80%]">
                <h3>
                    <b>Initiating</b> Gliclazide MR in patients who do not achieve
                    adequate glycemic control on Metformin
                    Monotherapy
                </h3>
            </div>

            <div class="flex gap-4 justify-between px-12 md:px-16 lg:px-32 xl:px-44 py-5 text-gray-500 font-semibold">
                <div class="border-2 border-dashed border-black py-1 xl:py-2 px-1 xl:px-8">
                    <p class="text-[6px] sm:text-xs md:text-base">
                        Number of CV Events/Deaths Avoided Per Year<br>
                        When Adding Gliclazide MR to Metformin
                    </p>
                </div>

                <div class="border-2 border-dashed border-black py-2 px-8">
                    <p class="text-[6px] sm:text-xs md:text-base">
                        Cost of CV Events / Deaths Avoided
                    </p>
                </div>
            </div>

            <div class="flex px-8 sm:px-6 lg:px-10 xl:px-20 justify-between items-center xl:gap-32">

                <div
                    class="bg-gray-200 w-[50%] rounded-[20px] xl:rounded-[60px] h-auto pt-0 pb-5 px-2 flex gap-2 xl:gap-8 justify-center items-start relative mt-6">

                    <!-- RED -->
                    <div class="relative">
                        <img src="./images/arrow-red-section-one.png" alt="Red Arrow" class="w-full">
                    </div>

                    <!-- BLACK -->
                    <div class="relative">
                        <img src="./images/arrow-black-section-one.png" alt="Black Arrow" class="w-full">
                    </div>

                </div>


                <div
                    class="relative w-[50%] min-h-[100px] sm:min-h-[200px] md:min-h-[300px] lg:min-h-[400px] xl:min-h-[500px] overflow-hidden flex items-center justify-center">

                    <!-- Money -->
                    <div class="absolute inset-0 
                bg-center bg-contain bg-no-repeat 
                opacity-40 " style="background-image: url('./images/money.png');">
                    </div>

                    <!-- Content -->
                    <div class="relative z-10 text-center">

                        <div class="flex items-center justify-center">

                            <span
                                class="mt-1 text-orange-400 text-xs sm:text-3xl md:text-5xl lg:text-6xl xl:text-7xl font-bold rotate-[-90deg]">
                                SAVE
                            </span>

                            <div>
                                <div class="flex items-end justify-center gap-1">
                                    <h2
                                        class="text-red-600 text-xs sm:text-3xl md:text-5xl lg:text-6xl xl:text-7xl font-extrabold">
                                        12,250
                                    </h2>
                                    <div class="text-left flex flex-col">
                                        <p
                                            class="text-red-600 text-[10px] sm:text-base md:text-xl lg:text-3xl xl:text-4xl font-extrabold">
                                            USD</p>
                                        <p
                                            class="text-red-600 text-[4px] sm:text-[6px] md:text-xs xl:text-base font-semibold">
                                            Per CV Event</p>
                                    </div>
                                </div>

                                <div class="mt-1 md:mt-4 lg:mt-8 xl:mt-12 flex items-end justify-center gap-1">
                                    <h2
                                        class="text-gray-500 text-xs sm:text-3xl md:text-5xl lg:text-6xl xl:text-7xl font-extrabold">
                                        189,415
                                    </h2>
                                    <div class="text-left flex flex-col">
                                        <p
                                            class="text-gray-500 text-[10px] sm:text-base md:text-xl lg:text-3xl xl:text-4xl font-extrabold">
                                            USD</p>
                                        <p
                                            class="text-gray-500 text-[4px] sm:text-[6px] md:text-xs xl:text-base font-semibold">
                                            Per Death</p>
                                    </div>
                                </div>
                            </div>

                        </div>

                    </div>

                </div>
            </div>
        </div>

        <!-- section two -->
        <div class="flex flex-col mt-10">
            <div
                class="text-white text-sm md:text-2xl p-6 sm:px-8 md:px-10 lg:px-14 xl:px-20 bg-orange-500 rounded-r-full w-[90%] xl:w-[80%]">
                <h3>
                    <b>Switching</b> the Add-On Treatment to Gliclazide MR in patients who do not achieve adequate
                    glycemic
                    control on Sitagliptin and Metformin

                </h3>
            </div>

            <div class="flex flex-col md:flex-row items-center justify-center gap-6 md:gap-10 mt-8 xl:mt-14 px-6">

                <!-- LEFT -->
                <div
                    class="relative w-full md:w-1/2 max-w-2xl aspect-[4/3] overflow-hidden flex items-center justify-center">

                    <!-- People background -->
                    <div class="absolute inset-0 
                    bg-center bg-contain bg-no-repeat" style="background-image: url('./images/people.png');">
                    </div>

                    <!-- Content -->
                    <div class="relative z-10 text-center text-white px-4">

                        <h1 class="text-5xl sm:text-7xl md:text-5xl lg:text-7xl xl:text-8xl"
                            style="text-shadow: 0 4px 6px rgba(0,0,0,0.5);">
                            +21,000
                        </h1>

                        <p class="inline bg-gray-400 px-2 py-0 leading-none text-base sm:text-2xl md:text-xl lg:text-3xl xl:text-4xl"
                            style="text-shadow: 0 4px 6px rgba(0,0,0,0.4);">
                            Additional patients achieve glycemic control
                        </p>

                    </div>
                </div>

                <!-- RIGHT -->
                <div
                    class="relative w-full md:w-1/2 max-w-2xl aspect-[4/3] bg-gray-300/30 rounded-2xl xl:rounded-[50px] overflow-hidden">

                    <!-- Money -->
                    <div class="absolute inset-0 bg-bottom bg-cover bg-no-repeat opacity-20"
                        style="background-image: url('./images/money.png');">
                    </div>

                    <!-- Arrows -->
                    <div class="absolute top-0 left-1/2 -translate-x-1/2 flex items-start gap-[4%] w-[75%] z-20">

                        <!-- RED (ใหญ่กว่า) -->
                        <img src="./images/arrow-red-section-two.png" class="w-[55%] h-auto" alt="">

                        <!-- BLACK (เล็กกว่า) -->
                        <img src="./images/arrow-black-section-two.png" class="w-[45%] h-auto" alt="">
                    </div>

                    <!-- Text -->
                    <div class="absolute top-[70%] left-1/2 -translate-x-1/2 -translate-y-1/2 text-center z-10">

                        <h2 class="text-lg sm:text-3xl md:text-2xl xl:text-4xl 
                       font-bold text-orange-500 tracking-wide" style="text-shadow: 0 4px 8px rgba(0,0,0,0.4);">
                            ANNUALLY SAVE
                        </h2>

                        <h1 class="text-3xl sm:text-5xl md:text-4xl xl:text-6xl 
                       font-extrabold text-red-600" style="text-shadow: 0 4px 8px rgba(0,0,0,0.4);">
                            5.11 m USD
                        </h1>
                    </div>

                </div>

            </div>

            <div class="flex flex-col text-gray-500 mx-4 md:mx-10 xl:mx-20 mt-10 text-xs md:text-sm xl:text-base">
                <div class="flex gap-1 md:gap-3 xl:gap-8">
                    <p>1.</p>
                    <p>
                        Farghaly M, Cristeau O, Awadi FAL, Al Dallal S. Cost-Consequences of Adding Gliclazide
                        Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab
                        Emirates. Adv Ther. 2025 Dec;42(12):6190-6208.
                    </p>
                </div>

                <div class="flex gap-1 md:gap-3 xl:gap-8">
                    <p>2.</p>
                    <p>
                        Diamicron MR 60 mg. Summary of Product Characteristic.
                    </p>
                </div>
            </div>

        </div>

        <!-- Section three -->
        <div class="flex flex-col mt-10 mx-4 md:mx-10 xl:mx-20">

            <!-- Text -->
            <div class="flex-col space-y-2 md:space-y-6 xl:space-y-8 text-gray-500 text-lg md:text-xl xl:text-3xl">
                <h2>
                    I look forward to discussing with you the use of Diamicron MR 60 mg for your patients with
                    uncontrolled type 2 diabetes with Metformin, whether as monotherapy or in combination with
                    Sitagliptin.
                </h2>
                <h2>
                    Best regards,<br>
                    Your Servier medical representative
                </h2>
            </div>

            <!-- Diamicron -->
            <div class="flex flex-col justify-center items-center text-center">
                <img class="w-[60%]" src="./images/diamicron.png" alt="">
                <h1 class="text-orange-400 text-xl md:text-3xl lg:text-5xl xl:text-7xl font-semibold leading-relaxed">
                    Diamicron MR 60 mg<br>
                    UP TO 2 TABLETS DAILY<sup>2</sup>
                </h1>
            </div>

            <!-- Text -->
            <div class="mt-10">
                <p class="text-xs md:text-sm xl:text-base">
                    This email was sent to you on behalf of SERVIER (THAILAND) because your email address is on our
                    subscribers list. This information is intended for health care professionals.
                </p>
            </div>

        </div>

        <!-- Section four -->
        <div class="flex flex-col mt-2">

            <div class="text-black bg-orange-200 w-[100%]">
                <p class="text-[10px] md:text-xs xl:text-sm p-3 xl:p-5">
                    COMPOSITION*: Diamicron 60 mg MR, modified release tablet containing 60 mg of gliclazide, contains
                    lactose as an excipient. INDICATIONS*: Non insulin-dependent diabetes (type 2) in adults when
                    dietary measures, physical exercise and weight loss alone are not sufficient to control blood
                    glucose. DOSAGE AND ADMINISTRATION*: One half to 2 tablets per day i.e. from 30 to 120 mg taken
                    orally as a single intake at breakfast time, including in elderly patients and those with mild to
                    moderate renal insufficiency with careful patient monitoring. The breakability of Diamicron 60 mg MR
                    enables flexibility of dosing to be achieved. In patients at risk of hypoglycemia, daily starting
                    dose of 30 mg is recommended. Combination with other antidiabetics: Diamicron 60 mg MR can be given
                    in combination with biguanides, alpha glucosidase inhibitors or insulin (under close medical
                    supervision). CONTRAINDICATIONS*: Hypersensitivity to gliclazide or to any of the excipients, other
                    sulfonylurea or sulphonamides; type 1 diabetes; diabetic pre-coma and coma, diabetic ketoacidosis;
                    severe renal or hepatic insufficiency (in these cases the use of insulin is recommended); treatment
                    with miconazole; lactation. WARNINGS*: Hypoglycemia may occur with all sulfonylurea drugs, in cases
                    of accidental overdose, when calorie or glucose intake is deficient, following prolonged or
                    strenuous exercise and in patients with severe hepatic or renal impairment. Hospitalization and
                    glucose administration for several days may be necessary. Patient should be informed of the
                    importance of following dietary advice, of taking regular exercise and of regular monitoring of
                    blood glucose levels. To be prescribed only in patients with regular food intake. Use with caution
                    in patients with G6PD-deficiency. Excipients: contains lactose. INTERACTIONS*: Risk of hypoglycemia
                    – contraindicated: miconazole; not recommended: phenylbutazone; alcohol; use with caution: other
                    antidiabetic agents, beta-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2-receptor
                    antagonists, MAOIs, sulfonamides, clarithromycin, NSAIDs. Risk of hyperglycaemia – not recommended:
                    danazol; use with caution: chlorpromazine at high doses; glucocorticoids; ritodrine; salbutamol;
                    terbutaline, Saint John’s Wort (hypericum perforatum) preparations. Risk of dysglycaemia – use with
                    caution: fluoroquinolones. Potentiation of anticoagulant therapy (e.g. warfarin), adjustment of the
                    anticoagulant may be necessary. PREGNANCY*: Change to insulin before a pregnancy is attempted, or as
                    soon as pregnancy is discovered. BREASTFEEDING*: contraindicated. FERTILITY*. DRIVE AND USE
                    MACHINES*: Possible symptoms of hypoglycemia to be taken into account especially at the beginning of
                    the treatment. UNDESIRABLE EFFECTS*: Hypoglycemia, abdominal pain, nausea, vomiting, dyspepsia,
                    diarrhea, constipation. Rare: changes in haematology generally reversible (anaemia, leucopenia,
                    thrombocytopenia, granulocytopenia). Raised hepatic enzymes levels (AST, ALT, alkaline phosphatase),
                    hepatitis (isolated reports). If cholestatic jaundice: discontinuation of treatment. Transient
                    visual disturbances at start of treatment. More rarely: rash, pruritus, urticaria, angioedema,
                    erythema, maculopapular rashes, bullous reactions such as Stevens-Johnson syndrome and toxic
                    epidermal necrolysis and autoimmune bullous disorders, and exceptionally, drug rash with
                    eosinophilia and systemic symptoms (DRESS). As for other sulfonylureas: observed cases of
                    erythrocytopenia, agranulocytosis, haemolytic anaemia, pancytopenia, allergic vasculitis,
                    hyponatraemia, elevated liver enzymes, impairment of liver function (cholestasis, jaundice) and
                    hepatitis which led to life-threatening liver failure in isolated cases. OVERDOSE* Possible severe
                    hypoglycemia requiring urgent IV glucose, immediate hospitalization and monitoring. PROPERTIES*:
                    Diamicron 60 mg MR is a sulfonylurea reducing blood glucose levels by stimulating insulin secretion
                    from beta cells in the islets of Langerhans, thereby restoring the first peak of insulin secretion
                    and increasing the second phase of insulin secretion in response to a meal or intake of glucose.
                    Independent haemovascular properties. PRESENTATION*: Box of 30, 90 tablets of Diamicron MR 60 mg in
                    blister. SERVIER (THAILAND) LTD., Bangkok, Thailand.
                </p>
            </div>

            <div class="flex flex-col text-xs md:text-sm lg:text-base xl:text-lg m-2 xl:m-5">
                <p>โปรดอ่านรายละเอียดเพิ่มเติมในเอกสารอ้างอิงฉบับสมบูรณ์และเอกสารกำกับยา</p>
                <p>Diamicron MR 60 mg เลขทะเบียนที่ 1C 19/54 (N)</p>
                <p>ใบอนุญาตโฆษณาเลขที่ ฆศ.2-59/2569</p>
                <p>ความถูกต้องของโฆษณานี้เป็นความรับผิดชอบของผู้โฆษณา มิได้ดำเนินการโดยสำนักงานคณะกรรมการอาหารและยา</p>
                <p>การโฆษณาตามใบอนุญาตนี้ต้องกระทําโดยตรงต่อผู้ประกอบโรคศิลปะ ผู้ประกอบวิชาชีพเวชกรรม
                    หรือผู้ประกอบการบําบัดโรคสัตว์เท่านั้น
                    ผู้ใดนําโฆษณานี้ไปเผยแพร่ต่อบุคคลอื่นที่ไม่ใช่ผู้ประกอบโรคศิลปะ</p>
                <p>ผู้ประกอบวิชาชีพเวชกรรม หรือผู้ประกอบการบําบัดโรคสัตว์ ถือเป็นการฝ่าฝืนมาตรา 88 และมาตรา 88 ทวิ
                    ต้องระวางโทษปรับไม่เกินหนึ่งแสนบาท ตามมาตรา 124 แห่งพระราชบัญญัติยาพ.ศ. 2510 และฉบับแก้ไขเพิ่มเติม
                </p>
            </div>
        </div>

    </section>

    <!-- Footer -->
    <footer
        class="w-[100%] h-[100px] lg:h-[120px] xl:h-[150px] flex items-end justify-between bg-blue-900 text-white text-[8px] sm:text-[12px] md:text-sm xl:text-lg">
        <p class="">© Servier Thailand.</p>
        <img class="w-[20%]" src="./images/logo2.png" alt="">
        <p>M-DIAMC-TH-202601-00001</p>
    </footer>
</body>

</html>